BioCentury
ARTICLE | Clinical News

Aldeyra starts Ph III of ADX-102 for non-infectious anterior uveitis

May 3, 2017 12:26 AM UTC

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) began a Phase III trial to evaluate 0.5% ADX-102 ophthalmic solution for 4 weeks in about 100 patients with non-infectious anterior uveitis. The primary endpoint of the double-blind, vehicle-controlled, U.S. trial is resolution of inflammation. ...

BCIQ Company Profiles

Aldeyra Therapeutics Inc.